Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
ERNA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
8 hours ago
globenewswire.com
9 hours ago
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
-1.06
vs -3.40
Q2.23
N/A
-0.85
vs -1.20
Q3.23
N/A
-1.03
vs -2.49
Q4.23
N/A
-1.14
vs -1.24
Q1.24
N/A
-1.23
vs -1.06
Q2.24
N/A
-1.02
vs -0.85
Q3.24
N/A
-4.92
vs -1.03
Q4.24
N/A
-1.14
vs -1.14
Q1.25
N/A
-2.25
vs -1.23
Q2.25
N/A
-0.61
vs -1.02
Sales Growth
YoY
Current
Estimates
Q1.23
NA
NA vs NA
Q2.23
NA
NA vs NA
Q3.23
NA
51K vs NA
Q4.23
NA
17K vs NA
Q1.24
NA
47K vs NA
Q2.24
NA
47K vs NA
Q3.24
+855%
487K vs 51K
Q4.24
-94%
1K vs 17K
Q1.25
-100%
NA vs 47K
Q2.25
-100%
NA vs 47K
Return on Equity
QoQ
Q1.23
-73%
-0.73
vs -0.37
Q2.23
-117%
-1.17
vs -0.73
Q3.23
-157%
-1.57
vs -1.17
Q4.23
-276%
-2.76
vs -1.57
Q1.24
+195%
1.95
vs -2.76
Q2.24
+65%
0.65
vs 1.95
Q3.24
+59%
0.59
vs 0.65
Q4.24
-339%
-3.39
vs 0.59
Q1.25
+138%
1.38
vs -3.39
Q2.25
-71%
-0.71
vs 1.38
Institutionnal Ownership
QoQ
Q4.22
18
18
vs NA
NA
Q1.23
19
19
vs 18
6%
Q2.23
19
19
vs 19
NA
Q3.23
19
19
vs 19
NA
Q4.23
19
19
vs 19
NA
Q1.24
22
22
vs 19
16%
Q2.24
19
19
vs 22
-14%
Q3.24
20
20
vs 19
5%
Q4.24
24
24
vs 20
20%
Q1.25
26
26
vs 24
8%
Forecast
2026-Revenue
-28916%2026-EPS
703%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available
Quote Panel
Key Metrics
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.
NASDAQ
Unprofitable
EPS improving
Unprofitable
EPS improving
0.03 ( 1.58%)
Relative Strenght
99
Volume Buzz
-56%
Earning Acce
No
Dist 52w H.
94%Relative Strength
ERNA
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|